Irritable bowel syndrome with constipation prevalence. Irritable bowel syndrome
Conditions
Interventions
Treatment - Drugs
Intervention 1: Control group: A similar medicinal product to the non-herbicide group was given as placebo for 6 weeks three times a day, each time 10 cc were given to the patients and the clinical ma
Placebo
Control group: A similar medicinal product to the non-herbicide group was given as placebo for 6 weeks three times a day, each time 10 cc were given to the patients and the clinical manifestations of
Intervention group: Syrup containing a certain amount of herbs of ARTEMISIA ABSINTHIUM, CUSCUTA EPITHYMUM, CASSIA FISTULA, ECHIUM AMOENIUM, MELLISA OFFICINALLIS weighing 10 cc three times a day for 6
Sponsors
Deputy of Research and Technology, Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: The criteria for entry are based on the diagnostic criteria of IBS, namely, ROME IV, which is as follows: (Recurrent abdominal pain at least one day a week in the last three months, with at least two of the following three characteristics: related to bowel movements - with a change in the frequency of bowel movements - accompanied by changes in the shape of the stool These symptoms start at least six months before the diagnosis.); constipation based on Bristrol Stool Form Scale; age between 18-50 years old; not having severe mental and behavioral disorders; no history of organic bowel disease; lack of pregnancy or breastfeeding; lack of drug addiction; no history of any major bowel surgery; serious and malignant systemic disease; the inability to use interfering chemical and vegetable medications with treatment. Exit criteria: pregnancy during the study; in the event of drug complications or other medical problems; unwillingness to continue treatment.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of disease, stool consistency,. Timepoint: At the beginning of the study and before starting treatment. Method of measurement: Illness severity questionnaire - IBS-SSS and Bristrol Stool Form Scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Anxiety and depression. Timepoint: 6 weeks after starting treatment and 4 weeks after treatment. Method of measurement: questionnaire severity of depression and anxiety-HADS-. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHamide Khorram Pajooh
Mashhad University of Medical Sciences
Outcome results
None listed